JP Morgan Chase
KYTX icon

JP Morgan Chase’s Kyverna Therapeutics KYTX Stock Holding History

JP Morgan Chase’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
22,984
+18,309
+392% +$163K ﹤0.01% 5612
2026
Q1 		$35.4K Buy
4,675
+401
+9% +$3.34K ﹤0.01% 6337
2025
Q4 		$40.2K Sell
4,274
-2,401
-36% -$17.8K ﹤0.01% 6312
2025
Q3 		$40K Sell
6,675
-21,180
-76% -$84.7K ﹤0.01% 6304
2025
Q2 		$85.5K Sell
27,855
-11,647
-29% -$28.8K ﹤0.01% 5677
2025
Q1 		$76.2K Sell
39,502
-2,126,935
-98% -$6.28M ﹤0.01% 5697
2024
Q4 		$8.1M Sell
2,166,437
-220,915
-9% -$1.06M ﹤0.01% 2898
2024
Q3 		$11.7M Buy
2,387,352
+326,095
+16% +$2.51M ﹤0.01% 2478
2024
Q2 		$15.5M Buy
2,061,257
+1,216,792
+144% +$18.6M ﹤0.01% 2074
2024
Q1 		$21M Buy
+844,465
New +$23.6M ﹤0.01% 1849

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

JP Morgan Chase's KYTX Position: Q2 2026 in Review

JP Morgan Chase increased its Kyverna Therapeutics (KYTX) stake by 392% in Q2 2026, buying an estimated $163K and bringing the position to 22,984 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #5612.

JP Morgan Chase first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $21M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • JP Morgan Chase held 22,984 shares of Kyverna Therapeutics worth $202K as of Q2 2026.
  • JP Morgan Chase bought 18,309 Kyverna Therapeutics shares in Q2 2026, an estimated $163K.
  • Kyverna Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5612 holding.
  • JP Morgan Chase first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • JP Morgan Chase's Kyverna Therapeutics position peaked at $21M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.